Europe Veterinary Antibiotics Market Size to Hit Around USD 2.32 Bn by 2033

Europe Veterinary Antibiotics Market Size to Hit Around USD 2.32 Bn by 2033

The Europe veterinary antibiotics market size was exhibited at USD 1.85 billion in 2023 and is projected to hit around USD 2.32 billion by 2033, growing at a CAGR of 2.27% during the forecast period 2024 to 2033.

Download Free Sample Copy for Better Understanding@ https://www.novaoneadvisor.com/report/sample/8744

Europe Veterinary Antibiotics Market Key Takeaways:

  • The cattle segment held the largest market share of 36.1% in 2023 and is also expected to grow at a significant CAGR of 2.4% during the forecast period.
  • The penicillins segment held the largest market share of more than 30.4% in 2023.
  • Sulfonamides segment is expected to grow at a significant CAGR during the forecast period.
  • The oral solutions segment held the largest market share of more than 51.0% in 2023 and it is also expected to grow at a significant CAGR during the forecast period.

The increasing prevalence of livestock diseases, growing awareness and adoption of pet healthcare, rising focus on animal-only antibiotics & ionophores, and growing product launches or other initiatives are driving the market growth. According to the German livestock data, the country has the largest dairy cattle herd and the second-largest cattle population in the EU. In addition, according to the International Committee for Animal Recording (ICAR), around 50% of German farms specialize in livestock, which is anticipated to create a conducive environment for the market.

One of the primary drivers of the market in Europe is the rising incidence of zoonotic diseases. Zoonotic diseases, which are infectious diseases that can be transmitted from animals to humans, pose a significant public health risk. The increase in livestock farming and pet ownership has amplified the risk of such diseases spreading, necessitating more vigilant and widespread use of antibiotics to control and prevent outbreaks. Veterinary antibiotics are essential in treating bacterial infections in animals, thus preventing the transmission of diseases to humans. As public health agencies and veterinary professionals emphasize the importance of controlling zoonotic diseases, the demand for effective veterinary antibiotics continues to grow.

The market is witnessing a shift toward animal-only antibiotics and ionophores. This trend is largely driven by factors such as antibiotic resistance and health & welfare concerns. The awareness about the relationship between the use of antibiotics in livestock and the development of antibiotic-resistant bacteria is growing, which may pose a threat to both animal and human health. As a result, there is a need to develop antibiotics that are exclusively used in animals to minimize the risk of cross-resistance.

Moreover, major players in the market have shifted their focus to animal-only antibiotics, as a measure to address antibiotic resistance while protecting animal health. For instance, Elanco introduced an antibiotic stewardship plan, which focuses on reducing shared-class antibiotics and increasing the production of animal-only antibiotics. In 2023, the revenue of animal-only antibiotics increased by 6% and represented 15% of Elanco’s total revenue. In 2023, ionophores accounted for over 90% of the revenue generated from antibiotics produced only for animals. Some of the animal-only antibiotics or ionophores available in the market are Maxiban & Monteban (used to prevent coccidiosis in poultry) and Rumensin (used to treat coccidiosis in cattle). Therefore, increasing focus on ionophores is expected to drive market growth over the forecast period.

Furthermore, the market is expected to grow at a significant pace due to favorable government regulations, such as the European Union (EU) Veterinary Medicines Regulation. According to an article published by the European Public Health Alliance, stringent regulations limiting the use of veterinary antibiotics came into effect across the EU in January 2022. These new regulations limit the use of antibiotics to prevent treatments for specific animals and their routine administration. Moreover, antimicrobials cannot substitute inadequate hygiene and animal husbandry practices. Furthermore, trade organizations, such as the European Free Trade Association (EFTA) between Liechtenstein, Iceland, Norway, and Switzerland, have encouraged trade between these countries and increased growth opportunities across Europe.

Europe Veterinary Antibiotics Market By Animal Type Insights

The cattle segment held the largest market share of 36.1% in 2023 and is also expected to grow at a significant CAGR of 2.4% during the forecast period. This dominance is attributed to the increased consumption of beef and dairy products and the high incidence of bacterial infections. In 2022, milk output in 27 Member States of the European Union (EU-27) is anticipated to increase by 0.2% to 150.45 million metric tons compared to 2021. Europe is renowned for its high-quality beef and dairy products, which enjoy strong domestic and international demand. This economic importance necessitates rigorous health management practices to ensure the productivity and quality of cattle herds.

Europe Veterinary Antibiotics Market By Drug Class Insights

The penicillins segment held the largest market share of more than 30.4% in 2023 due to its broad-spectrum efficacy, established safety profile, cost-effectiveness, and regulatory support for its responsible use. Penicillin is one of the most commonly sold antibiotic classes for veterinary applications. On the basis of chemical structure, penicillins are divided into monobactams and carbapenems. Based on the spectrum, it is classified as narrow, extended, and broad. Similarly, on the basis of source, it is divided into synthetic, semisynthetic, and natural. Penicillin veterinary antibiotics are widely manipulated to improve their spectrum, pharmacological characteristics, efficacy, and resistance to β-lactamase destruction. Penicillins are widely available in various formulations, including injectable, oral, and topical formulations, making them convenient for different animal species and infections. According to the Republic of Estonia Agency of Medicines, the percentage of sales of penicillins was 29.5% in 2023.

Europe Veterinary Antibiotics Market By Dosage Form Insights

The oral solutions segment held the largest market share of more than 51.0% in 2023 and it is also expected to grow at a significant CAGR during the forecast period. This dominance is driven by a combination of factors including ease of administration, higher compliance rates, cost-effectiveness, versatility across different animal species, and advancements in formulation technologies. Oral antibiotics can be conveniently administered to animals through their drinking water or feed, reducing the stress and discomfort associated with other routes of administration, such as injections. This method is particularly advantageous for large-scale livestock operations, where administering injections to hundreds or thousands of animals would be labor-intensive and logistically challenging.


Oral solutions streamline the treatment process, making it more efficient and manageable for farmers and veterinarians. Some large animal farms use automatic metering devices or medication proportions to treat a large number of animals at the same time. According to EMA, oral antimicrobial solutions sales in over 31 EU countries were estimated to be 57% in 2020, which exhibits their wide suitability for veterinary treatments in European animal farms. Moreover, compared to other dosage forms, such as injectables or topical applications, oral solutions are generally less expensive to produce and administer. This cost-efficiency is crucial for the livestock industry, where profit margins can be tight, and cost control is essential. By reducing the overall cost of treatment, oral solutions help farmers maintain the health of their herds economically, supporting their widespread use.

Country Insights

Germany Veterinary Antibiotics Market Trends

The veterinary antibiotics market in Germany is expected to grow over the forecast period due to the rising animal adoption such as pets and growing animal husbandry. According to the International Committee for Animal Recording (ICAR), around 50% of German farms specialize in livestock, which is anticipated to create a conducive environment for the market. The growing awareness about the significance of farm & companion animal health and the rising partnerships & collaborations among key players are major factors expected to fuel market growth. For instance, in January 2024, TheraVet, a leading company specializing in the management of osteoarticular diseases in pets, commercially launched its BIOCERA-VET products in Germany. Such innovations in the country are anticipated to fuel market growth over the estimated period.

UK Veterinary Antibiotics Market Trends

The veterinary antibiotics market in UK is expected to grow at a CAGR of 2.49% over the forecast period. Various factors contributing to this growth include increased pet ownership and insurance. As the insurance policies cover the cost of veterinary care, pet owners are more inclined to take their animals to veterinary hospitals & clinics for diagnosis and treatment, which is expected to improve the need for animal antibiotics or animal drugs. The People’s Dispensary for Sick Animals (PDSA), a leading veterinary charity in the UK, provides low-cost and free treatments to animals in need. As the prevalence of injury and illnesses is growing among companion animals, the need for proper treatment is expected to grow. According to PDSA’s statistics, around 800 cases a month require emergency surgery and are treated at PDSA charity animal hospital.

Spain Veterinary Antibiotics Market Trends

The veterinary antibiotics market in Spain is expected to grow over the forecast period rapid growth in the livestock sector and the increasing meat production & consumption. According to the Food & Wines from Spain’s data, the country has approximately 6.4 million heads of cattle (almost half are cows). In addition, the Autonomous Communities of Spain have the largest beef cattle, including Castile-La Mancha, Castile-Leon, Extremadura, and Aragon. Moreover, the rising pet adoption, the growing number of veterinarian clinics, and the increasing owner awareness, leading to a surge in annual veterinary treatment spending, are expected to fuel market growth over the forecast period. For instance, according to Protectapet, there are 6,000+ veterinarian clinics in the country catering to nearly 17 million pets. In addition, the country’s veterinarian clinics offer various services and collective treatment for the pet patient population.

Europe Veterinary Antibiotics Market Recent Developments

  • In July 2023, Bimeda Biologicals introduced Stimulator 5 + PMH, an MLV vaccine combining viral and bacterial antigens to combat Bovine Respiratory Disease (BRD).
  • In June 2023, Norbrook launched Tauramox, the first generic injectable solution for moxidectin, providing effective control of various internal and external parasites in beef and nonlactating dairy cattle.
  • In May 2023, Virbac acquired GS Partners, its long-standing distributor in the Czech Republic & Slovakia, marking its 35th subsidiary and reinforcing its presence in Central Europe. With the acquisition, Virbac aimed to enhance its ability to meet the health needs of animals in the region, particularly in the pet & ruminant sectors.

Some of the prominent players in the Europe veterinary antibiotics market include:

  • Merck & Co., Inc.
  • Ceva Sante Animale
  • Vetoquinol
  • Zoetis Services LLC
  • Boehringer Ingelheim International GmbH
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Virbac S.A.
  • Calier
  • Bimeda, Inc.
  • Prodivet Pharmaceuticals SA/NV
  • Norbrook Laboratories

Reasons to Purchase this Report

  • Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
  • Provision of market value (USD Billion) data for each segment and sub-segment
  • Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
  • Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
  • Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
  • Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
  • The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
  • Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
  • Provides insight into the market through Value Chain
  • Market dynamics scenario, along with growth opportunities of the market in the years to com

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Europe veterinary antibiotics market

Animal type

  • Pigs
  • Cattle
  • Sheep & Goats
  • Poultry
  • Others

Drug class

  • Tetracyclines
  • Penicillins
  • Sulfonamides
  • Macrolides
  • Trimethoprim
  • Lincosamides
  • Polymyxins
  • Aminoglycosides
  • Fluoroquinolones
  • Pleuromutilins
  • Other Drug Class

Dosage form

  • Oral Powders
  • Oral Solutions
  • Injections
  • Other Dosage Forms

Country

  • Germany
  • UK
  • Netherlands
  • Belgium
  • Denmark
  • France
  • Italy
  • Spain
  • Hungary
  • Poland
  • Portugal
  • Romania
  • Sweden
  • Norway
  • Rest of Europe

Quick Buy This Premium Report From Here: https://www.novaoneadvisor.com/report/checkout/8744?

Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com

You can place an order or ask any questions, please feel free to [email protected]| +1 9197 992 333

About US

Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

Connect with Us

Address: Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

IND Address: 2nd Floor,Shreeleela Plaza, Baner Road, Pune, Maharashtra - 411045

Call: USA - +1 650 460 3308 | IND - +91 87933 22019

[email protected]

Web: https://www.novaoneadvisor.com/

Nova One Advisor Group Offer Other Reports:

Cell Therapy Market Size and Forecast:?The global?cell therapy market size was exhibited at USD 4.85 billion in 2023 and is projected to hit around USD 37.42 billion by 2033, growing at a CAGR of 22.67% during the forecast period 2024 to 2033.

Gene Therapy Market Size and Forecast?:?The global?gene therapy market size was exhibited at USD 8.75 billion in 2023 and is projected to hit around USD 52.40 billion by 2033, growing at a CAGR of 19.6% during the forecast period 2024 to 2033.

Cell And Gene Therapy Manufacturing Market Size and Forecast:?The global?cell and gene therapy manufacturing market size was estimated at USD 9.95 billion in 2023 and is projected to hit around USD 106.03 billion by 2033, growing at a CAGR of 26.7% during the forecast period from 2024 to 2033.

Cell and Gene Therapy Market?Size and Forecast:?The global?cell and gene therapy market size was estimated at USD 18.13 billion in 2023 and is projected to hit around USD 97.33 billion by 2033, growing at a CAGR of 18.3% during the forecast period from 2024 to 2033.

U.S. Cell Therapy Market Size and Forecast:?The?U.S. cell therapy market size was estimated at USD 2.88 billion in 2023 and is projected to hit around USD 19.67 billion by 2033, growing at a CAGR of 21.18% during the forecast period from 2024 to 2033.

U.S. Gene Therapy Market Size and Forecast:?The?U.S. gene therapy market size?was estimated at USD 3.19 billion in 2023 and is projected to hit around USD 18.50 billion by 2033, growing at a CAGR of 19.22% during the forecast period from 2024 to 2033.

T-cell Therapy Market Size and Forecast:?The global?T-Cell therapy market size?was exhibited at USD 3.85 billion in 2023 and is projected to hit around USD 79.62 billion by 2033, growing at a CAGR of 35.38% during the forecast period 2024 to 2033.

Cancer Immunotherapy Market?Size and Forecast:?The global?cancer immunotherapy market?size was valued at USD 126.19 billion in 2023 and is projected to surpass around USD 296.01 billion by 2033, registering a CAGR of 8.9% over the forecast period of 2024 to 2033.

Immunotherapy Drugs Market?:?The global?immunotherapy drugs market size was valued at USD 240.19 billion in 2023 and is projected to surpass around USD 1,300.38 billion by 2033, registering a CAGR of 18.4% over the forecast period of 2024 to 2033.

Clinical Trials Market Size and Forecast:?The?global clinical trials market size was estimated at USD 81.90 billion in 2023 and is projected to hit around USD 153.59 billion by 2033, growing at a CAGR of 6.49% during the forecast period from 2024 to 2033.

Biologics Market Size and Forecast: The?global biologics market size was estimated at USD 511.04 billion in 2023 and is projected to hit around USD 1,374.51 billion by 2033, growing at a CAGR of 10.4% during the forecast period from 2024 to 2033.

Biotechnology Market Size and Forecast:? The?global biotechnology market size was estimated at USD 1.54 Trillion in 2023 and is projected to hit around USD 5.68 Trillion by 2033, growing at a CAGR of 13.95% during the forecast period from 2024 to 2033.

Oncology? Market Size and Forecast: The?global oncology market size was estimated at USD 222.36 billion in 2023 and is projected to hit around USD 521.60 billion by 2033, growing at a CAGR of 8.9% during the forecast period from 2024 to 2033.

Cell And Gene Therapy Clinical Trials?Market Size and Forecast: The global cell and gene therapy clinical trials market size reached USD 11.62 billion in 2023 and is projected to hit around USD 47.40 billion by 2033, expanding at a CAGR of 15.09% during the forecast period from 2024 to 2033.

U.S. Clinical Trials Market Size and Forecast:?The?U.S. clinical trials market size was valued at USD 25.81 billion in 2023 and is projected to surpass around USD 41.57 billion by 2033, registering a CAGR of 4.88% over the forecast period of 2024 to 2033.

要查看或添加评论,请登录

Vijay Anger的更多文章

社区洞察

其他会员也浏览了